Phase II study of SNJ-2022; An exploration study in patients with primary open angle glaucoma or ocular hypertension - An exploration study of SNJ-2022 in patients with primary open angle glaucoma or ocular hypertension

Senju Pharmaceutical co.,ltd.0 个研究点目标入组 120 人开始时间: 2015年9月28日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1)Any active ocular disease other than glaucoma or OH 2)Active retinal disease 3)History of keratorefractive surgery, filtering surgery, trabeculotomy in the study eye 4)Ocular surgery within 3 months in the study eye 5)Use of contact lenses 6)Allergy or serious side effect to alpha2-adrenergic agonist 7)Use of alpha-adrenoceptor agonist, alpha-adrenoceptor antagonist, beta-adrenergic agonist, beta-adrenoceptor antagonist, MAO inhibitor, adrenergic-augmenting psychotropic drugs, Central Nervous System Depressant 8)Patient with Impaired liver function, kidney disorder, depression, raynaud disease, thromboangiitis obliterans, orthostatic hypotension, cerebrovascular occlusion, coronary vessel occlusion, compromised circulation of serious cardiovascular disease 9)Women who were pregnant, nursing or who were of childbearing potential, or planning a pregnancy 10)Highly visual field loss 11)Corneal abnormalities that would preclude accurate readings with an applanation tonometer

发起方